Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment
Brief Summary: The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C.


Options:
A: Arm Label: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-790052; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV
B: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
C: Arm Label: Group A: T12/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group B: T12(DS)/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group C: Pbo/PR48; Type: EXPERIMENTAL; Interventions: Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48
D: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV

Answer: C